TADA2B

Across TCGA pan-cancer cohorts, TADA2B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TADA2B data layer compared with 20 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TADA2B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TADA2B expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where TADA2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.344	0.680	.001	17	view →
LSCC	OS	Median	II,III,IV	0.948	0.721	.003	12	view →
LUAD	DFS	Median	III,IV	0.283	0.871	.020	4	view →
HNSC	DFS	Quartile	IV	1.000	0.700	.042	2	view →
CCRCC	OS	Median	III,IV	0.415	0.845	.016	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TADA2B–PDAC (OS)

Open the PDAC breakdown →